Vaccine Technologies Market By Type (DNA Vaccines, mRNA Vaccines, Protein Subunit Vaccines, Virus-Like Particle (VLP) Vaccines, Live Attenuated Vaccines, Inactivated Vaccines), By Application (Human Vaccines, Animal Vaccines, Infectious Disease Vaccines, Cancer Vaccines), By End-User Industry (Pharmaceuticals, Biotechnology, Healthcare, Contract Research Organizations (CROs), Government & Non-Governmental Organizations (NGOs), Academic & Research Institutes), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Vaccine Technologies Market was valued at USD 7.8 billion in 2024-e and will surpass USD 18.1 billion by 2030; growing at a CAGR of 12.9% during 2025 - 2030.

The vaccine technologies market has seen remarkable growth in recent years, driven by advancements in biotechnology and a heightened global focus on pandemic preparedness. This sector encompasses a wide range of vaccine platforms designed to target various infectious diseases and conditions. The increased demand for vaccines, particularly after the COVID-19 pandemic, has sparked innovation and substantial investment in new vaccine technologies. From DNA and mRNA vaccines to traditional methods like inactivated and live attenuated vaccines, each technology offers distinct advantages and is suited for specific applications. As the global population grows and the need for efficient, rapid vaccine deployment increases, the market for vaccine technologies is expected to continue its upward trajectory.

mRNA Vaccines Segment is Fastest Growing Owing to Pandemic Success

Among the diverse vaccine technologies, mRNA vaccines have emerged as the fastest-growing segment in recent years. The success of mRNA vaccines in combating the COVID-19 pandemic has significantly boosted interest and investment in this technology. mRNA vaccines work by instructing cells in the body to produce a protein that induces an immune response, providing protection against specific pathogens. The speed at which mRNA vaccines can be developed and manufactured, combined with their adaptability to different diseases, has made them an attractive option for addressing global health challenges. Additionally, mRNA technology is being explored for use in vaccines targeting a range of infectious diseases, including malaria, HIV, and influenza, further accelerating market growth.

Human Vaccines Segment is Largest Due to Widespread Demand

The human vaccines segment is the largest within the vaccine technologies market, largely driven by the need for immunization against infectious diseases like COVID-19, influenza, and others. Human vaccines are critical for preventing disease outbreaks, controlling pandemics, and maintaining public health. With the global population growing, the demand for effective and scalable human vaccines continues to rise, further solidifying this segment as the market leader. In particular, the expansion of immunization programs, both in developed and developing countries, plays a key role in sustaining this demand. As governments and organizations push for mass vaccination campaigns, the human vaccines segment will remain a significant contributor to the overall growth of the vaccine technologies market.

Pharmaceuticals Segment is Largest End-User Industry

In terms of end-users, the pharmaceuticals industry stands out as the largest contributor to the vaccine technologies market. Pharmaceutical companies are the primary entities responsible for developing, producing, and distributing vaccines on a global scale. With vast resources and a strong research and development infrastructure, pharmaceutical companies play a pivotal role in advancing vaccine technologies. The rapid development of COVID-19 vaccines, spearheaded by companies like Pfizer and Moderna, highlights the pharmaceuticals industry's crucial role in vaccine innovation. As these companies expand their portfolios to include vaccines for other diseases, their influence in the vaccine technologies market will continue to grow, ensuring that the pharmaceuticals sector remains a key driver of market expansion.

North America Region is Largest in Vaccine Technologies Market

Regionally, North America holds the largest share of the vaccine technologies market, primarily due to the advanced healthcare infrastructure and strong investment in research and development. The region has been a leader in vaccine innovation, with companies like Pfizer, Moderna, and Johnson & Johnson driving the development of cutting-edge technologies. Government initiatives, including funding for vaccine research and public health campaigns, further bolster North America's dominance in this market. Additionally, the growing focus on healthcare and the increasing demand for vaccines, particularly in response to COVID-19, has accelerated market growth in the region. North America is expected to maintain its leadership position in the vaccine technologies market as the demand for innovative vaccines continues to rise.

Leading Companies and Competitive Landscape

The vaccine technologies market is highly competitive, with several key players driving innovation across various segments. Leading companies in the market include Pfizer, Moderna, Johnson & Johnson, Sanofi, AstraZeneca, and GlaxoSmithKline, among others. These companies invest heavily in research and development to stay at the forefront of vaccine technology advancements, particularly in mRNA, protein subunit, and DNA vaccines. As the market grows, competition is expected to intensify, with both established pharmaceutical giants and emerging biotech companies vying for market share. Additionally, collaborations and partnerships between pharmaceutical companies, academic institutions, and governments are likely to shape the future landscape of the vaccine technologies market. The rapid pace of innovation, combined with increased demand for vaccines, will continue to fuel a dynamic competitive environment.

The market's future will also be influenced by regulatory agencies like the FDA, EMA, and WHO, which play a crucial role in vaccine approvals, ensuring that vaccine technologies meet stringent safety and efficacy standards. With growing investment and research, the vaccine technologies market is poised for continued expansion, providing a significant opportunity for both established and new market players

Recent Developments:

• Moderna announced a collaboration with Merck to develop personalized cancer vaccines using mRNA technology. The agreement is set to accelerate cancer vaccine research.
• AstraZeneca plans to expand its manufacturing facilities to meet the global demand for COVID-19 vaccines, with a focus on scaling up the production of viral vector vaccines.
• Pfizer is expanding its mRNA vaccine platform to include vaccines for malaria. The new vaccine candidate is in the early stages of clinical trials, with results expected in the coming years.
• Novavax’s COVID-19 vaccine, developed using a protein subunit technology, has received Emergency Use Authorization (EUA) in the European Union, marking a significant milestone for the company.
• Sanofi has acquired Translate Bio to strengthen its mRNA vaccine capabilities, signaling an increased focus on mRNA vaccine technology in future vaccine development.

List of Leading Companies:

• Pfizer Inc.
• Moderna, Inc.
• Sanofi Pasteur
• Johnson & Johnson
• AstraZeneca
• Novavax
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Bayer AG
• Bharat Biotech
• Sinovac Biotech
• Clover Biopharmaceuticals
• Vaxine Pty Ltd
• Emergent BioSolutions
• MedImmune

Report Scope: